GO:1905101 negative regulation of apoptosome assembly: Apoptosis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905101 describes any process that stops, prevents or reduces apoptosome assembly, the platform that activates caspase-9 during intrinsic apoptosis.
• Calcium blocks apoptosome formation by preventing nucleotide exchange in Apaf-1, a direct biochemical example of negative regulation.
• Cytochrome c is best known as an apoptosome activator, but it can also negatively regulate NLRP3 inflammasomes, showing crosstalk between apoptotic and inflammatory platforms.
• The term is a biological_process child of negative regulation of apoptosome assembly and is distinct from positive regulation of apoptosome assembly.
• Loss of negative regulation can shift cells toward excessive or insufficient apoptosis, which is relevant to cancer, neurodegeneration and inflammatory disease.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the main tools for testing whether a candidate gene causally controls apoptosome assembly.
Description
GO:1905101, negative regulation of apoptosome assembly, is a Gene Ontology biological_process term that captures any mechanism which stops, prevents or reduces the frequency, rate or extent of apoptosome assembly. The apoptosome is a cytosolic platform that forms when cytochrome c is released from mitochondria and binds Apaf-1, triggering caspase-9 activation and intrinsic apoptosis. Because apoptosome assembly is a commitment step for cell death, its negative regulation is a critical checkpoint in development, tissue homeostasis and disease. Experimental work has shown that calcium can directly block apoptosome formation by preventing nucleotide exchange in Apaf-1, providing a concrete biochemical route for this GO term. More broadly, cytochrome c has been reported to negatively regulate NLRP3 inflammasomes, indicating that molecules classically associated with apoptosis can also restrain related innate immune platforms. For researchers, GO:1905101 is therefore not an abstract annotation but a testable set of molecular events that determine whether a cell lives or dies.
negative regulation of apoptosome assembly At A Glance
| GO ID | GO:1905101 |
|---|---|
| GO term | negative regulation of apoptosome assembly |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of apoptosome assembly. |
| Synonym | down regulation of apoptosome assembly; down-regulation of apoptosome assembly; downregulation of apoptosome assembly; down regulation of apoptosome formation; down-regulation of apoptosome formation; downregulation of apoptosome formation; inhibition of apoptosome assembly; inhibition of apoptosome formation; negative regulation of apoptosome formation |
| Major function | Restrains formation of the Apaf-1/cytochrome c/caspase-9 apoptosome platform and thereby limits intrinsic apoptosis. |
| Example regulator | Calcium blocks apoptosome formation by preventing nucleotide exchange in Apaf-1. |
| Related process | Cytochrome c can also negatively regulate NLRP3 inflammasomes, linking apoptotic and inflammatory control. |
| Research relevance | A causal checkpoint for cancer, neurodegeneration and inflammatory disease models. |
What Is GO:1905101?
In plain terms, GO:1905101 means any cellular process that reduces how often, how fast or how completely the apoptosome is built. The apoptosome is the Apaf-1/cytochrome c/caspase-9 complex that drives mitochondrial apoptosis, so negative regulation of its assembly is a brake on that death pathway. The QuickGO definition is: any process that stops, prevents or reduces the frequency, rate or extent of apoptosome assembly. Synonyms include down regulation of apoptosome assembly, inhibition of apoptosome assembly and negative regulation of apoptosome formation.
Why Is negative regulation of apoptosome assembly Important in Cell Biology?
Negative regulation of apoptosome assembly is important because apoptosome formation is a point of no return for intrinsic apoptosis, and its suppression can decide whether a cell survives a stress signal. When this brake fails, cells may die excessively, contributing to degenerative disease; when the brake is too strong, damaged cells may survive, contributing to cancer or autoimmunity. The term also matters because it connects apoptosis to inflammation: cytochrome c, a canonical apoptosome activator, has been shown to negatively regulate NLRP3 inflammasomes, revealing crosstalk between cell-death and innate immune platforms. For drug discovery and CRISPR functional genomics, GO:1905101 provides a precise annotation target for genes that modulate Apaf-1 nucleotide exchange, apoptosome stability or upstream mitochondrial release events.
• Apoptosome assembly is a commitment step in intrinsic apoptosis, so its negative regulation directly controls cell fate.
• Calcium-mediated prevention of Apaf-1 nucleotide exchange is a validated biochemical mechanism of negative regulation.
• Cytochrome c can restrain NLRP3 inflammasomes, linking GO:1905101-related biology to inflammation.
• Dysregulated apoptosome control is relevant to cancer, where too little apoptosis allows survival of damaged cells.
• Excessive apoptosome activity is relevant to neurodegeneration and ischemic injury, where too much cell death occurs.
• The term supports CRISPR screens that ask which genes causally suppress apoptosome assembly.
• It provides a precise GO annotation for interpreting RNA-seq, proteomics and interactome data.
• It helps distinguish negative regulation of apoptosome assembly from positive regulation and from downstream caspase inhibition.
• It is a useful readout for mitochondrial stress, cytochrome c release and Apaf-1 conformational change.
• It supports development of small molecules or biologics that tune apoptosis for therapeutic benefit.
What Happens During negative regulation of apoptosome assembly?
Blocking Apaf-1 nucleotide exchange
In simple terms: Apaf-1 needs to swap nucleotides to switch on, and calcium can jam that switch.
Apaf-1 is an AAA+ ATPase-like protein that must exchange nucleotide to adopt an active conformation competent for apoptosome assembly. Calcium blocks formation of the apoptosome by preventing nucleotide exchange in Apaf-1, which is a direct molecular mechanism of negative regulation. This means that negative regulation of apoptosome assembly can occur at the level of Apaf-1 conformational activation rather than only at the level of cytochrome c release.
Limiting cytochrome c availability or activity
In simple terms: If cytochrome c cannot reach Apaf-1, the apoptosome cannot be built.
Apoptosome assembly requires cytochrome c released from mitochondria to bind Apaf-1. Any process that reduces cytosolic cytochrome c availability, or that alters cytochrome c in a way that prevents Apaf-1 activation, will negatively regulate apoptosome assembly. Cytochrome c has also been shown to negatively regulate NLRP3 inflammasomes, indicating that its functions extend beyond being a simple apoptosome trigger.
Preventing Apaf-1 oligomerization
In simple terms: The apoptosome is a wheel-like oligomer, so stopping Apaf-1 from clustering stops the platform.
Apoptosome assembly proceeds through Apaf-1 oligomerization into a wheel-like complex that recruits caspase-9. Negative regulation can therefore act by stabilizing Apaf-1 in a monomeric or assembly-incompetent state. Calcium-dependent inhibition of nucleotide exchange is one example of how this oligomerization step can be prevented.
Crosstalk with inflammatory platforms
In simple terms: The same molecules that control apoptosis can also calm inflammation.
Cytochrome c negatively regulates NLRP3 inflammasomes, showing that a molecule central to apoptosome biology can restrain an inflammatory complex. This crosstalk means that negative regulation of apoptosome assembly may be studied alongside innate immune signaling. It also suggests that perturbations of apoptosome regulators could have inflammatory consequences beyond apoptosis.
Downstream consequences for caspase-9 activation
In simple terms: No apoptosome means no caspase-9 activation and less cell death.
The apoptosome is the platform that recruits and activates caspase-9, so negative regulation of apoptosome assembly reduces caspase-9 activation. This places GO:1905101 upstream of caspase-9 and downstream of mitochondrial cytochrome c release. Assays for caspase-9 activity, caspase-3/7 activity and apoptosis are therefore functional readouts of this GO term.
Key Genes Involved in GO:1905101 negative regulation of apoptosome assembly
The genes and proteins most directly tied to GO:1905101 include the apoptosome core components and the molecules reported to restrain their assembly.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APAF1 | Core apoptosome scaffold; requires nucleotide exchange for activation | Central target for negative regulation by calcium and other inhibitors |
| CYCS | Cytochrome c released from mitochondria; binds APAF1 to trigger assembly | Can also negatively regulate NLRP3 inflammasomes |
| CASP9 | Initiator caspase recruited and activated by the apoptosome | Downstream readout of apoptosome assembly |
| CASP3 | Executioner caspase activated downstream of caspase-9 | Apoptosis readout for functional studies |
| CASP7 | Executioner caspase in the intrinsic apoptosis pathway | Apoptosis readout for functional studies |
| NLRP3 | Inflammasome sensor negatively regulated by cytochrome c | Links GO:1905101 biology to inflammation |
| BCL2 | Anti-apoptotic mitochondrial regulator upstream of cytochrome c release | Controls cytochrome c availability for apoptosome assembly |
| BCL2L1 | Anti-apoptotic BCL-2 family member (BCL-xL) | Modulates mitochondrial outer membrane permeabilization |
| MCL1 | Anti-apoptotic BCL-2 family member | Supports survival by limiting cytochrome c release |
| BAX | Pro-apoptotic effector of mitochondrial permeabilization | Promotes cytochrome c release and apoptosome assembly |
| BAK1 | Pro-apoptotic effector of mitochondrial permeabilization | Promotes cytochrome c release and apoptosome assembly |
| DIABLO | Mitochondrial protein released with cytochrome c; modulates IAPs | Context for apoptosome-associated death signaling |
| XIAP | Inhibitor of apoptosis protein that restrains caspases | Downstream brake on apoptosis, distinct from apoptosome assembly |
| AIFM1 | Mitochondrial flavoprotein involved in caspase-independent death | Context for alternative death pathways |
| ENDOG | Endonuclease released from mitochondria during apoptosis | Context for mitochondrial death signaling |
| TP53 | Stress transcription factor that can promote intrinsic apoptosis | Upstream regulator of apoptotic priming |
| AKT1 | Survival kinase that can suppress intrinsic apoptosis | Upstream survival signaling context |
How Is negative regulation of apoptosome assembly Regulated?
Negative regulation of apoptosome assembly is controlled at multiple levels. At the core, calcium prevents nucleotide exchange in Apaf-1, directly blocking formation of the apoptosome. Upstream, BCL-2 family proteins control mitochondrial outer membrane permeabilization and therefore the release of cytochrome c that is required for assembly. Cytochrome c itself has been reported to negatively regulate NLRP3 inflammasomes, showing that the same molecule can participate in both apoptotic and inflammatory control circuits. These layers mean that GO:1905101 should be interpreted as an integrated checkpoint rather than a single reaction.
negative regulation of apoptosome assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APAF1 | Apoptosis dysregulation in cancer and degeneration | APAF1 knockout and point-mutation cell lines with apoptosome assembly assays |
| CYCS | Apoptosis and NLRP3 inflammasome crosstalk | CYCS knockout or overexpression with inflammasome and caspase-9 readouts |
| CASP9 | Intrinsic apoptosis competence | CASP9 knockout cells for caspase-9 activation assays |
| BCL2 | Cancer cell survival and chemoresistance | BCL2 overexpression and knockout models with cytochrome c release assays |
| NLRP3 | Inflammatory disease and inflammasome activation | NLRP3 reporter cells treated with cytochrome c or apoptosome modulators |
Cancer
Cancers often evade apoptosis by shifting the balance away from apoptosome assembly, for example by increasing anti-apoptotic BCL-2 family proteins or by reducing cytochrome c release. Negative regulation of apoptosome assembly is therefore a conceptual brake whose excessive activity can support tumor cell survival. Experimental models that measure apoptosome formation and caspase-9 activation can test whether a candidate gene contributes to this survival phenotype.
Neurodegeneration and ischemic injury
In conditions where excessive apoptosis contributes to cell loss, loss of negative regulation of apoptosome assembly could worsen injury. Calcium is a well-known mediator of neuronal stress, and its ability to block Apaf-1 nucleotide exchange provides a direct link between calcium signaling and apoptosome control. Studying GO:1905101 in neuronal models can clarify whether restoring this brake is protective.
Inflammatory disease
Cytochrome c negatively regulates NLRP3 inflammasomes, connecting apoptosome-related molecules to inflammatory disease biology. This means that perturbations in negative regulation of apoptosome assembly could have consequences beyond cell death, including altered inflammasome activity. Models that combine apoptosis and inflammasome readouts are useful for dissecting this crosstalk.
From negative regulation of apoptosome assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase apoptosome assembly? | CRISPR knockout cell line with Apaf-1/caspase-9 assembly assays |
| Does a specific residue control Apaf-1 nucleotide exchange? | Point-mutation knock-in of APAF1 at the nucleotide-binding site |
| Does a disease variant alter negative regulation of apoptosome assembly? | Knock-in of the patient variant with caspase-9 activation readout |
| Where does a regulator localize during apoptosis? | Endogenous tagged knock-in with imaging and co-immunoprecipitation |
| Does overexpression of a regulator block apoptosome formation? | Doxycycline-inducible overexpression cell line |
| Does cytochrome c modulate inflammatory platforms? | CYCS knockout or overexpression with NLRP3 inflammasome readouts |
How to Study the negative regulation of apoptosome assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Native gel or gel filtration | Apaf-1 oligomerization and apoptosome assembly | Testing negative regulators of assembly |
| Caspase-9 activity assay | Activation of initiator caspase downstream of apoptosome | Functional readout of GO:1905101 |
| Caspase-3/7 assay | Executioner caspase activity and apoptosis | Confirming cell-death outcome |
| Cytochrome c release assay | Mitochondrial outer membrane permeabilization | Distinguishing upstream vs direct regulation |
| Nucleotide exchange assay | Apaf-1 conformational activation | Testing calcium or small-molecule inhibition |
| NLRP3 inflammasome assay | Inflammatory platform activation | Studying crosstalk with apoptosis |
| CRISPR knockout screen | Genes whose loss changes apoptosis or assembly | Discovery of new negative regulators |
| Proteomics or interactomics | Protein complexes associated with Apaf-1 or cytochrome c | Mapping the apoptosome regulatory network |
Apoptosome assembly assays
Biochemical reconstitution and gel-filtration or native gel assays can measure Apaf-1 oligomerization and apoptosome formation in response to cytochrome c and nucleotides. These assays directly test negative regulation because they detect the assembly state of the platform. Calcium treatment is a validated way to block nucleotide exchange and prevent assembly in such systems.
Caspase activation and apoptosis readouts
Caspase-9, caspase-3 and caspase-7 activity assays, together with Annexin V or viability assays, report the functional consequence of apoptosome assembly. If a candidate gene negatively regulates assembly, its loss should increase caspase-9 activation under apoptotic stimuli. These readouts are standard for validating CRISPR models of GO:1905101.
Mitochondrial cytochrome c release
Imaging and fractionation methods can measure cytochrome c release from mitochondria, which is upstream of apoptosome assembly. Combining release measurements with assembly assays distinguishes upstream mitochondrial control from direct Apaf-1 regulation. This is important because negative regulation can act at either level.
Inflammasome crosstalk assays
Because cytochrome c negatively regulates NLRP3 inflammasomes, NLRP3 activation assays can be combined with apoptosis readouts. Such experiments test whether a perturbation of apoptosome regulation also changes inflammatory signaling. This integrated approach is useful for disease models where both pathways are relevant.
How CRISPR Can Be Used to Study GO:1905101 negative regulation of apoptosome assembly
Knockout
CRISPR knockout of candidate genes is used to test whether removing a putative brake increases apoptosome assembly and caspase-9 activation. For example, knocking out an Apaf-1 inhibitor should sensitize cells to cytochrome c-induced assembly. Knockout models are also the starting point for genome-wide screens of GO:1905101.
Point Mutation
Point mutations in APAF1 can be introduced to test residues required for nucleotide exchange and calcium sensitivity. Such models separate direct effects on Apaf-1 activation from upstream mitochondrial effects. They are especially useful when a disease variant is suspected to alter apoptosome regulation.
Knock-in
Knock-in of tags or patient variants allows endogenous-level study of apoptosome regulators. Tagged knock-in enables imaging and co-immunoprecipitation without overexpression artifacts. Variant knock-in can test whether a specific allele changes negative regulation of apoptosome assembly.
Overexpression
Inducible overexpression of a candidate negative regulator can test whether increased dosage blocks apoptosome formation. Overexpression of cytochrome c pathway components can also be used to probe crosstalk with NLRP3 inflammasomes. These models complement knockout by testing sufficiency rather than necessity.
How EDITGENE Supports negative regulation of apoptosome assembly Research
Researchers studying negative regulation of apoptosome assembly-related genes often need to determine whether a candidate gene is causally involved in controlling Apaf-1 activation, cytochrome c availability or downstream caspase-9 activity. EDITGENE provides the CRISPR cell models and screening services needed to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of apoptosome assembly research.
Frequently Asked Questions About negative regulation of apoptosome assembly
What is GO:1905101?
GO:1905101 is the Gene Ontology biological_process term for negative regulation of apoptosome assembly, meaning any process that stops, prevents or reduces apoptosome formation.
What is negative regulation of apoptosome assembly?
It is the set of cellular mechanisms that reduce how often, how fast or how completely the Apaf-1/cytochrome c/caspase-9 apoptosome is assembled.
What genes are involved in negative regulation of apoptosome assembly?
Key genes include APAF1, CYCS, CASP9 and BCL-2 family members, with cytochrome c also linked to NLRP3 inflammasome control.
How does calcium block apoptosome assembly?
Calcium blocks formation of the apoptosome by preventing nucleotide exchange in Apaf-1, which is required for its activation.
Why is negative regulation of apoptosome assembly important in cancer?
Too much negative regulation can help cancer cells avoid apoptosis, so understanding this brake is relevant to survival and chemoresistance.
Does cytochrome c only activate apoptosis?
No. Cytochrome c is required for apoptosome assembly, but it has also been shown to negatively regulate NLRP3 inflammasomes.
What assays measure negative regulation of apoptosome assembly?
Apaf-1 oligomerization assays, caspase-9 activity assays, cytochrome c release assays and apoptosis readouts are commonly used.
Can CRISPR be used to study GO:1905101?
Yes. CRISPR knockout, point-mutation, knock-in and overexpression models are used to test causal roles of candidate genes in apoptosome regulation.
What is the difference between apoptosome assembly and caspase activation?
Apoptosome assembly is the formation of the Apaf-1 platform, while caspase activation is the downstream consequence of that platform recruiting caspase-9.
Which diseases are linked to apoptosome regulation?
Cancer, neurodegeneration, ischemic injury and inflammatory conditions are relevant because they involve altered apoptosis or inflammasome signaling.
Conclusion
GO:1905101, negative regulation of apoptosome assembly, defines the cellular brakes on the Apaf-1/cytochrome c/caspase-9 platform that commits cells to intrinsic apoptosis. Calcium-mediated prevention of Apaf-1 nucleotide exchange provides a direct mechanism, while cytochrome c crosstalk with NLRP3 inflammasomes links this process to inflammation. For researchers, the term offers a precise framework for CRISPR functional studies of cell-fate control in cancer, degeneration and inflammatory disease.
References
- 1. Shi CS et al.. 2016. Cytochrome c Negatively Regulates NLRP3 Inflammasomes.. PLoS One 11(12):e0167636 PMID: 28030552
- 2. Bao Q et al.. 2007. Calcium blocks formation of apoptosome by preventing nucleotide exchange in Apaf-1.. Mol Cell 25(2):181-92 PMID: 17244527
